Objective To conduct a retrospective study of usage of cinobufagin preparations in hospitalized tumor patients in order to provide reference for rational use of cinobufagin.Method The PASSPharmaAssist system was used to retrieve data of patients from Weifang People's Hospital who used cinobufagin preparations between 1 January,2020 and 31 August,2023.The demographic data,diagnostic information,and usage were statistically analyzed using Excel 2016 software.Results A total of 463 patients were enrolled,and 629 cases of the use of cinobufagin preparations.The survey found that among tumor patients,males[with an average age of(63.00±9.70)years,accounting for(57.02%)]outnumbered females[with an average age of(59.11±10.83)years,accounting for(42.98%)],with an average age of(61.31±10.37)years.The top five types of cancers involved were lung cancer(44.45%),colorectal cancer(28.94%),gastric cancer(9.51%),esophageal cancer(4.10%),and liver cancer(3.02%),The dominating medication regimens involving cinobufagin were combined chemotherapy(36.57%).In addition,there were cases of combined use with immune checkpoint inhibitors,targeted drugs,analgesics and radiotherapy(230 cases).Among them,77 cases(33.48%)had no ADR,119 cases(51.74%)were general ADR and 34 cases(14.78%)were serious ADR.In clinical practice,there was excessive dosage,and the courses of medication were mostly less than 10 days.Conclusion Cinobufagin is primarily used in the treatment of lung cancer and gastrointestinal cancer,especially before and during chemotherapy.The clinical efficacy and mechanism of action remain to be verified and elucidated,and there is still a lack of consensus on the course of medication.It is necessary to be vigilant against cardiac toxicity caused by excessive doses.
维普
万方数据